Ralph Weichselbaum

Dr. Ralph R. Weichselbaum is the D.K. Ludwig Professor and Chairman of Radiation and Cellular Oncology at the University of Chicago. He is the Director of the Ludwig Center for Metastasis Research and holds over 30 patents in gene therapy and angiogenesis inhibitors with radiation and chemotherapy. Dr. Weichselbaum was a founding scientist in GenVec and Convergence Therapeutics and was a consulting scientist for Medigene. Weichselbaum’s work has been published in Nature, Science, Nature Medicine, PNAS, Gene Therapy, JCI, JBC and the New England Journal of Medicine as well as the specialty cancer journals Cancer Research and JNCI.

He lists over 600 publications and is the co-editor of Cancer Medicine, a comprehensive textbook on cancer. He was awarded the Hines Professorship at the University of Chicago in 1992 and the Ludwig Professorship in 1998. He was named Head of the Program in Molecular Oncology in 2000 and is a member of the Institute of Medicine of the National Academy of Sciences. Dr. Weichselbaum has devoted his career to translational research in cancer. While a faculty member in radiation therapy and cancer biology at Harvard in the 1970’s and 1980’s, Weichselbaum defined the role of potentially lethal radiation damage in human tumor cells and the role of this type of DNA repair in radiotherapy.

He became head of the section of radiotherapy at the Dana Farber/Brigham and Woman’s Hospital and made major contributions to the treatment of head and neck cancer with combined radiotherapy and chemotherapy. Dr. Weichselbaum came to the University of Chicago in late 1984 and established the first department of radiation and cellular oncology which is one of the dominant academic departments in the U.S.

Ralph Weichselbaum is the Professor and Chairman of Radiation and Cellular Oncology at University of Chicago. With a background in Education, Ralph Weichselbaum has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.